Aleafia Health - CEO, Geoffrey Benic
CEO, Geoffrey Benic
Source: Aleafia Health
  • Aleafia Health (AH) has begun to export dried flower into Germany, gaining access to Europe’s most mature legal cannabis market
  • The first shipment, from Aleafia’s Niagara greenhouse facility, features the company’s signature THC cultivar Sour Kush
  • The European cannabis market is expected to be worth US$4.7 billion by 2025, with Germany representing nearly half the total market size
  • The company informs that it is currently fulfilling successive purchase orders to Germany
  • Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company
  • Aleafia Health (AH) is trading flat at $0.44 per share

Aleafia Health (AH) has begun to export dried flower into Germany, gaining access to Europe’s most mature legal cannabis market.

The first shipment, from Aleafia’s Niagara greenhouse facility, features the company’s signature THC cultivar Sour Kush. While dried flower available in Germany is largely irradiated, the product shipped exceeded quality standards and did not require irradiation, offering a significant competitive advantage in product quality.

The company completed the export through a strategic partner’s EU-GMP-certified facility.

Germany is the second major medical cannabis market the company has exported to.

The European cannabis market is expected to be worth US$4.7 billion by 2025, with Germany alone representing nearly half the total market size, according to research from Prohibition Partners.

The company informs that it is currently fulfilling successive purchase orders to Germany.

In addition, Aleafia has secured import and export permits for two additional orders to Australia with shipments expected to occur in June.

 Geoffrey Benic, Aleafia Health’s CEO, commented,

“The investments we’ve made in the highest levels of global regulatory compliance are just now beginning to pay dividends as we gain access to the largest medical cannabis market in the world. The shipment itself is an incredibly important breakthrough. More importantly, it represents an entirely new sales channel that will deliver consistent, repeatable revenue.

With such high barriers to entry, the German cannabis market opportunity perfectly complements this quarter’s continued growth in our domestic medical and adult-use channels.”

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company.

Aleafia Health (AH) is trading flat at $0.44 per share as of 11:36 am ET.

More From The Market Online

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.

The Market Online’s Weekly Cannabis Report – May 10, 2024

A leading North American cannabis and consumer packaged goods company will acquire key players in its U.S. expansion strategy.

Canopy Growth prepares for U.S. expansion with new acquisitions

Canopy Growth (TSX:WEED) exercises its options to acquire Wana and Jetty Extracts, key players in the company's U.S. expansion strategy.